To systematically review the efficacy and safety of Guigan Longmu Decoction in the treatment of premature ventricular contraction(PVC).Methods:CNKI，Cochrane Library，WanFang Data，Pubmed、SinoMed，EMbase，VIP databases were searched to collect randomized controlled trials (RCTs) about the treatment of PVC from inception to March，2020.A total of 2 researchers independently participated in the process of literature screening，data extraction and risk assessment，and then used Revman 5.3 for meta-analysis.Results:A total of 18 RCTs involving 1 377 patients were included.The results of meta-analysis showed that,the effect rate RR=1.26，95%CI 1.18 to 1.34，P<0.000 01; curative effect on symptoms RR=1.23，95%CI 1.14 to 1.33，P<0.000 01; improve effect on dynamic electrocardiogram(DCG) MD=-424.99，95%CI -640.98 to -209.00，P=0.000 1; curative effect on TCM symptoms MD=-4.45，95%CI -5.83 to -3.07，P<0.000 01; rate of adverse reactions RR=0.39，95%CI 0.23 to 0.67，P=0.0007.Conclusion:Guigan Longmu Decoction has more significant curative effect than control group，both with efficacy and safety.The quantity and quality of this study limited conducts more large sample RCT with rigorous control，multicenter，random，double blind and prospect to provide more evidence for clinical support.